Revolution Medicines Statistics
Share Statistics
Revolution Medicines has 182.35M shares outstanding. The number of shares has increased by 1.98% in one year.
| Shares Outstanding | 182.35M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 1.24% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 152.85M |
| Failed to Deliver (FTD) Shares | 5.49K |
| FTD / Avg. Volume | 0.35% |
Short Selling Information
The latest short interest is 18.14M, so 10.79% of the outstanding shares have been sold short.
| Short Interest | 18.14M |
| Short % of Shares Out | 10.79% |
| Short % of Float | 12.87% |
| Short Ratio (days to cover) | 14.94 |
Valuation Ratios
The PE ratio is -7.44 and the forward PE ratio is -14.72.
| PE Ratio | -7.44 |
| Forward PE | -14.72 |
| PS Ratio | 280.24 |
| Forward PS | 2050.8 |
| PB Ratio | 1.78 |
| P/FCF Ratio | -9.06 |
| PEG Ratio | n/a |
Enterprise Valuation
Revolution Medicines Inc. has an Enterprise Value (EV) of 2.64B.
| EV / Earnings | -6.04 |
| EV / Sales | 227.71 |
| EV / EBITDA | -6.12 |
| EV / EBIT | -5.41 |
| EV / FCF | -7.36 |
Financial Position
The company has a current ratio of 13.06, with a Debt / Equity ratio of 0.
| Current Ratio | 13.06 |
| Quick Ratio | 13.06 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.4 |
| Cash Flow / Debt | -47.57 |
| Interest Coverage | -1607.87 |
Financial Efficiency
Return on equity (ROE) is -0.24% and return on capital (ROIC) is -25.25%.
| Return on Equity (ROE) | -0.24% |
| Return on Assets (ROA) | -0.21% |
| Return on Capital (ROIC) | -25.25% |
| Revenue Per Employee | 23.63K |
| Profits Per Employee | -890.54K |
| Employee Count | 490 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -3.52M |
| Effective Tax Rate | 0.01 |
Stock Price Statistics
The stock price has increased by 68.94% in the last 52 weeks. The beta is 1.4, so Revolution Medicines 's price volatility has been higher than the market average.
| Beta | 1.4 |
| 52-Week Price Change | 68.94% |
| 50-Day Moving Average | 52.18 |
| 200-Day Moving Average | 42.49 |
| Relative Strength Index (RSI) | 29.03 |
| Average Volume (20 Days) | 1.56M |
Income Statement
In the last 12 months, Revolution Medicines had revenue of $11.58M and earned -$436.37M in profits. Earnings per share was $-3.86.
| Revenue | 11.58M |
| Gross Profit | 11.58M |
| Operating Income | -487.19M |
| Net Income | -436.37M |
| EBITDA | -430.58M |
| EBIT | -487.19M |
| Earnings Per Share (EPS) | -3.86 |
Balance Sheet
The company has $696.15M in cash and $87.94M in debt, giving a net cash position of $608.20M.
| Cash & Cash Equivalents | 696.15M |
| Total Debt | 87.94M |
| Net Cash | 608.20M |
| Retained Earnings | -1.14B |
| Total Assets | 1.76B |
| Working Capital | 1.47B |
Cash Flow
In the last 12 months, operating cash flow was -$350.57M and capital expenditures -$7.73M, giving a free cash flow of -$358.30M.
| Operating Cash Flow | -350.57M |
| Capital Expenditures | -7.73M |
| Free Cash Flow | -358.30M |
| FCF Per Share | -3.17 |
Margins
Gross margin is 100%, with operating and profit margins of -4.21K% and -3.77K%.
| Gross Margin | 100% |
| Operating Margin | -4.21K% |
| Pretax Margin | -3.80K% |
| Profit Margin | -3.77K% |
| EBITDA Margin | -3.72K% |
| EBIT Margin | -4.21K% |
| FCF Margin | -3.09K% |
Dividends & Yields
RVMD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -8.58% |
| FCF Yield | -4.37% |
Analyst Forecast
The average price target for RVMD is $62, which is 37.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $62 |
| Price Target Difference | 37.8% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
Scores
| Altman Z-Score | 23.58 |
| Piotroski F-Score | 2 |